KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 93 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,808,456 | +1.4% | 187,794 | -5.2% | 0.00% | – |
| Q2 2023 | $1,782,639 | +565.8% | 198,071 | +481.5% | 0.00% | – |
| Q1 2023 | $267,751 | -63.1% | 34,065 | -68.2% | 0.00% | – |
| Q4 2022 | $724,976 | -48.0% | 107,245 | +11.6% | 0.00% | – |
| Q3 2022 | $1,394,000 | +45.4% | 96,100 | -1.4% | 0.00% | – |
| Q2 2022 | $959,000 | +28.4% | 97,500 | +92.5% | 0.00% | – |
| Q1 2022 | $747,000 | -30.8% | 50,658 | -38.0% | 0.00% | – |
| Q4 2021 | $1,080,000 | -59.0% | 81,646 | -45.8% | 0.00% | – |
| Q3 2021 | $2,631,000 | -37.6% | 150,772 | -14.3% | 0.00% | – |
| Q2 2021 | $4,216,000 | -36.3% | 175,953 | -31.7% | 0.00% | -100.0% |
| Q1 2021 | $6,616,000 | -37.1% | 257,520 | -53.5% | 0.00% | – |
| Q4 2020 | $10,520,000 | +581.8% | 553,966 | +695.6% | 0.00% | – |
| Q2 2019 | $1,543,000 | +12.2% | 69,625 | +44.9% | 0.00% | -100.0% |
| Q1 2019 | $1,375,000 | +45.7% | 48,060 | +0.5% | 0.00% | – |
| Q4 2018 | $944,000 | – | 47,821 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |